Biotron Ltd. (BITRF) Starts Presentation at Biotech Showcase Conference

Biotron Ltd. (OTC: BITRF) is an Australian biotechnology company based in Sydney. The company develops and commercializes novel small molecule antiviral therapeutics targeting Hepatitis C virus (HCV) and HIV-1. Biotron’s lead drug, BIT225 is in clinical development for treatment of both HIV and HCV, as well as the hard to treat HIV/HCV co-infected population. Biotron also has early stage programs targeting other viruses including Dengue and has a research and development program for next generation viroporin inhibitors for its HIV/HCV programs. For more information, visit the company’s website at www.biotron.com.au